南華生物(000504.SZ):控股股東就公開徵集轉讓7%股份 共收到1家意向受讓方
格隆匯7月13日丨南華生物(000504.SZ)公佈,2021年7月13日,公司收到控股股東湖南省財信產業基金管理有限公司(“財信產業基金”)轉來的《關於公開徵集協議轉讓南華生物醫藥股份有限公司7%股份進展的函》,具體內容如下:
“我司於2021年6月29日通過貴司發佈了《擬通過公開徵集受讓方的方式協議轉讓公司部分股權的公開徵集信息公吿》,截至2021年7月12日公開徵集期滿,我司共收到1家意向受讓方即頂寅通宸(上海)股權投資基金管理有限公司遞交的意向受讓申請材料,意向受讓方擬使用以其作為管理人的專項合夥企業進行股權受讓,意向受讓方能否通過我司的評審尚存在不確定性。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.